ERBB2 and breast carcinoma: In a clinical study, constitutive presence of HER4 has been directly related with sensitivity to anti-HER2 drugs in breast cancer [42] whereas in prostate cancer an increase of HER4 expression has been shown to be responsible of resistance to the EGFR inhibitor erlotinib [43].